使用免疫检查点抑制剂（ICIs）治疗各种癌症的免疫疗法的最新进展也凸显了包括肝炎在内的免疫相关不良事件的增加，可能导致治疗的停止。本研究旨在评估接受不同 ICI 治疗的转移性结直肠癌 (mCRC) 患者的肝炎患病率。截至 2023 年 11 月，对 PubMed、PubMed Central 和 Google Scholar 的广泛搜索发现了相关研究。在排除非英文文章、病例报告、评论、正在进行的试验以及结合其他疗法的研究后，有五项研究符合纳入条件。分别使用Excel和综合荟萃分析软件进行数据提取和统计分析。亚组分析结果表明，PD-1单药治疗、PDL-1单药治疗以及PD-1和CTLA-4联合治疗的患者肝炎发生率相当，分别为2.6%、2.2%和1.7%对于任何级别，对于 ≥3 级肝炎分别为 2.1%、2.2% 和 1.7%。初次接受治疗的转移性结直肠癌患者的肝炎发生率高于既往接受治疗的患者（任何级别和≥3级的肝炎发生率分别为3.2% vs 1.6%和2.6% vs 1.6%）。这项研究强调了不同 ICI 疗法之间的肝炎风险相似，未经治疗的转移性结直肠癌 (mCRC) 患者的发病率有所增加。版权所有 © 2024 贝勒大学医学中心。

Recent advances in immunotherapy using immune checkpoint inhibitors (ICIs) for various cancers have also highlighted a rise in immune-related adverse events, including hepatitis, potentially leading to the discontinuation of treatment. This study aimed to evaluate the prevalence of hepatitis in metastatic colorectal cancer (mCRC) patients undergoing different ICI therapies. An extensive search of PubMed, PubMed Central, and Google Scholar up to November 2023 identified relevant studies. After excluding non-English articles, case reports, reviews, ongoing trials, and studies combining other therapies, five studies qualified for inclusion. Data extraction and statistical analyses were performed using Excel and Comprehensive Meta-Analysis software, respectively. Results from a subgroup analysis indicated that the incidence of hepatitis was comparable among patients treated with PD-1 monotherapy, PDL-1 monotherapy, and combination PD-1 and CTLA-4 therapy, with rates of 2.6%, 2.2%, and 1.7% for any grade and 2.1%, 2.2%, and 1.7% for grade ≥3 hepatitis, respectively. Naive-treated mCRC patients exhibited higher hepatitis rates than those previously treated (3.2% vs 1.6% and 2.6% vs 1.6% for any grade and grade ≥3, respectively). This study underscores the similar risk of hepatitis across different ICI therapies, with an increased incidence in naive-treated mCRC patients.Copyright © 2024 Baylor University Medical Center.